SINGAPORE -- Cancer antibody developer Hummingbird Bioscience has received approval from Singapore health authorities to start a clinical trial for COVID-19 antibody therapy.
Early trials are ongoing while a Phase 3 trial is scheduled for the end of the year. The latest trial will study the safety and efficacy of the experimental treatment HMBD-115, the company said.
